Global Auto-Injectors Market 2023

$2,950.00

製品コード: GM04952R 業界: 領域:
市場概況

The global auto-injectors market exhibits strong growth potential, forecast to grow at a CAGR of 13.4% から 2022-2029 to reach a value of USD 101.8 10億まで 2029. Rising prevalence of chronic conditions like rheumatoid arthritis, multiple sclerosis and anaphylaxis which require regular self-administration of medication. This drives demand for convenient auto-injector devices among patients.

Technological advancements enabling minimally invasive drug delivery, shorter needle lengths for improved comfort, and add-on monitoring tools to track dosage. Companies are innovating to enhance performance and user experience. Favorable trends like the shift towards home healthcare due to COVID-19 pandemic restrictions, and the growing geriatric population susceptible to chronic illnesses. This is increasing adoption of self-injectable devices.

しかし, the preference among some patient populations for alternative delivery methods like pre-filled syringes, pens, and pumps may restrain uptake. Complex regulatory requirements also pose hurdles in new product approvals.

市場セグメンテーション

The market is segmented based on product type, route of administration, therapy, エンドユーザー, そして地理.

Segmentation by Product Type
Disposable Autoinjectors
Reusable Autoinjectors

Segmentation by Route of Administration
Intramuscular
Subcutaneous

Segmentation by Therapy
Anaphylaxis
Diabetes
Multiple Sclerosis
Rheumatoid Arthritis
その他 (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia)

Segmentation by End User
Ambulatory Care
Home Care Settings
Hospital and Clinics

Segmentation by Geography
北米 – アメリカ, カナダ, メキシコ
ヨーロッパ – イギリス, ドイツ, フランス, イタリア, スペイン, およびその他のヨーロッパ
アジア太平洋地域 – 中国, 日本, インド, オーストラリア, 韓国, およびその他のアジア太平洋地域
ラテンアメリカ – ブラジル, アルゼンチン, およびその他のラテンアメリカ諸国
中東とアフリカ – GCC, 南アフリカ, およびその他の中東およびアフリカ

Rheumatoid arthritis (RA) represents a key therapy area driving growth within the global auto-injectors market. RA is an autoimmune condition causing chronic joint inflammation and pain due to the immune system mistakenly attacking healthy tissue. It has higher prevalence among the elderly female population.

As populations age, the incidence of RA is expected to increase, along with demand for self-injectable treatments that are convenient and simple to administer. Studies demonstrate RA patients using auto-injectors have better outcomes and find the devices more comfortable versus conventional injections by caregivers.

Companies are also promoting improved user experience through design advancements like hidden needles and ergonomic shapes. Such initiatives around patient centricity and innovation are catalyzing uptake of auto-injectors for RA treatment.

Geographically, North America accounts for a major share of the disposable auto-injectors market. Early adoption of new products, a steady pace of regulatory approvals and rising chronic disease prevalence make the region conducive for market growth. Specifically, the United States represents a lucrative market, aided by rapid uptake of technological advancements, new product introductions and expanding patient populations requiring self-administered drug delivery.

競争環境

The Auto-Injectors market is highly competitive and includes major players like Abbvie Inc., Amgen Inc., Antares Pharma, 株式会社. (Halozyme Therapeutics, 株式会社), Becton Dickinson and Co., Eli Lilly and Company, GSK plc, ジョンソン & ジョンソン, メルクKGaA, Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Ypsomed AG, とりわけ, who hold a significant market share.

最近の業界の発展

In May 2022, Jabil Healthcare, a division of Jabil Inc., launched the Qfinity autoinjector platform, providing a cost-effective solution for subcutaneous drug self-administration.

Also in May 2022, Stevanato Group S.p.A. formed an exclusive agreement with Owen Mumford Ltd. for its Aidaptus auto-injector.

報告書の範囲

To analyze and forecast the market size of the global auto-injectors market.
To classify and forecast the global auto-injectors market based on product type, route of administration, therapy, エンドユーザー, 地理.
To identify drivers and challenges for the global auto-injectors market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global auto-injectors market.
To identify and analyze the profile of leading players operating in the global auto-injectors market.

このレポートを選択する理由

Gain a reliable outlook of the global auto-injectors market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.

Global Auto-Injectors Market 2023

このレポートに興味がある? 今すぐ無料サンプルを入手してください!
Global Auto-Injectors Market 2023 - レポートの範囲
レポート属性

詳細

市場規模 (2022)

米ドル 42.2 十億

基準年

2022

予測年

2023-2029

CAGR (2023-2029)

13.4%

ページ

89

セグメント化基準

製品の種類, Route Of Administration, Therapy, エンドユーザー, 地理

対象地域

グローバル

キープレーヤー

Abbvie Inc., Amgen Inc., Antares Pharma Inc. (Halozyme Therapeutics Inc.), Becton Dickinson and Co., Eli Lilly and Company, GSK plc, ジョンソン & ジョンソン, メルクKGaA, Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Ypsomed AG

関連レポート
このレポートをカスタマイズしたい?
このレポートには、お客様の特定のニーズに合わせて調整できる柔軟性があります。. 当社のアナリストと業界専門家のチームは、お客様と直接協力して、お客様の要件を包括的に理解します。.
トップにスクロールします

無料サンプルをダウンロード - Global Auto-Injectors Market 2023

フォームにご記入ください。折り返しご連絡させていただきます.